



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Allegra Peletta,
✉ allegra.peletta@ugent.be

RECEIVED 30 October 2024
ACCEPTED 03 December 2024
PUBLISHED 16 December 2024

CITATION
Peletta A, Marmy A, Guzelj S, Ramos Barros A,
Jakopin Ž and Borchard G (2024) Corrigendum:
Preliminary results on novel adjuvant
combinations suggest enhancement
immunogenicity of whole inactivated pandemic
influenza vaccines.
Front. Drug Deliv. 4:1519969.
doi: 10.3389/fddev.2024.1519969

COPYRIGHT
© 2024 Peletta, Marmy, Guzelj, Ramos Barros,
Jakopin and Borchard. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines

Allegra Peletta^{1*}, Aurélie Marmy¹, Samo Guzelj²,
Alcidia Ramos Barros¹, Žiga Jakopin² and Gerrit Borchard¹

¹Section of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, Geneva, Switzerland, ²Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

KEYWORDS

pandemic influenza vaccine, adjuvant, hybrid PLGA nanoparticle, tomatine saponin, NOD2 agonists, formulation, immunogenicity

A Corrigendum on
[Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines](#)

by Peletta A, Marmy A, Guzelj S, Ramos Barros A, Jakopin Ž and Borchard G (2024). *Front. Drug Deliv.* 4:1382266. doi: [10.3389/fddev.2024.1382266](https://doi.org/10.3389/fddev.2024.1382266)

In the published article, there was an error in the **Funding** statement. “Swiss National founding, grant no: 20 IZCOZ0_182947” was included incorrectly. Instead, it should appear as “Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.” The correct **Funding** statement appears below.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.

In the published article, there was an error. The following sentence was mistakenly not included in the **Acknowledgments**: “The research was funded by Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.”

The correct **Acknowledgments** appears below:

“The authors would like to warmly thank the Vaccine Formulation Institute, particularly Dr. Nicolas Collin, Dr. Stéphanie Romand, Dr. Céline Lemoine, Dr. Livia Brunner, and Florian Gobet for their huge contribution to the project. They specifically thank Dr. Romand for the development of the LC-MS protocol, M. Gobet for his help with

animal studies, and Dr. Lemoine and Dr. Brunner for their help in building the project as well as advice on multiple occasions. The research was funded by Swiss National Science Foundation (SNF), grant no: IZCOZ0_182947.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.